Good morning :)
Place Order
Add to Watchlist

Unichem Laboratories Ltd

UNICHEMLAB

Unichem Laboratories Ltd

UNICHEMLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,169 cr, stock is ranked 760
High RiskStock is 3.01x as volatile as Nifty
746.701.70% (+12.50)
746.701.70% (+12.50)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,169 cr, stock is ranked 760
High RiskStock is 3.01x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,169 cr, stock is ranked 760
High RiskStock is 3.01x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-85.342.19
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
52.446.700.47%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs or bulk actives).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.1%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.58% to 0.48%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,351.39882.813,553.471,280.291,195.841,285.331,317.341,381.541,804.501,822.97
Raw Materialssubtract476.53262.42387.73477.13422.92467.52457.36533.73743.721,738.04
Power & Fuel Costsubtract38.2541.6249.2376.3973.0268.8978.05102.84107.14
Employee Costsubtract255.92169.04200.64238.52273.28306.97330.49356.41393.06
Selling & Administrative Expensessubtract380.90233.92291.18420.94345.54316.35287.13299.84361.41
Operating & Other expensessubtract20.6932.1017.9350.5639.77-15.3645.07134.33124.94
Depreciation/Amortizationsubtract38.7943.5250.5167.3781.6784.3691.17113.44113.24112.80
Interest & Other Itemssubtract2.903.368.017.527.855.126.1117.3122.6620.93
Taxes & Other Itemssubtract29.30-11.853.34-34.3511.9717.15-11.0925.868.8011.77
EPS11.9111.96315.72-3.38-8.554.884.69-28.72-10.01-8.60
DPS2.003.005.004.004.004.004.004.000.000.00
Payout ratio0.170.250.020.820.850.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2016

Annual Report Unavailable

Investor Presentation

Jun 1PDF
Feb 4PDF
FY 2017

Annual Report Unavailable

Investor Presentation

Jun 9PDF
Feb 6PDF
Nov 4PDF
Aug 16PDF
FY 2018

Annual Report Unavailable

FY 2019

Annual Report Unavailable

 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Unichem Laboratories Ltd-73.352.19
Sun Pharmaceutical Industries Ltd47.856.830.71%
Cipla Ltd31.324.820.81%
Torrent Pharmaceuticals Ltd71.3117.230.80%

Price Comparison

Compare UNICHEMLAB with any stock or ETF
Compare UNICHEMLAB with any stock or ETF
UNICHEMLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding70.22%10.22%1.44%0.94%17.18%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep1.62%0.83%0.84%0.90%0.89%0.94%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Unichem Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Small Cap Fund - Growth - Direct Plan

Growth
7.1984%1.06%0.14%23/92 (+1)
DSP Healthcare Fund - Growth - Direct Plan

Growth
0.9175%1.56%-0.01%20/33 (-2)
Franklin India Opportunities Fund - Growth - Direct Plan

Growth
0.6882%0.64%0.01%66/72 (-10)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 1, 2022

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Aug 1, 2022

Cash Dividend

Ex DateEx DateJul 22, 2021

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 22, 2021

Cash Dividend

Ex DateEx DateAug 20, 2020

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Aug 20, 2020

Cash Dividend

Ex DateEx DateJul 18, 2019

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 18, 2019

Cash Dividend

Ex DateEx DateJul 19, 2018

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 19, 2018

News & Opinions
Corporate
Unichem Laboratories to hold board meeting

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 30 September 2024.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Board of Unichem Laboratories to consider proposal for consolidation of generic formulations biz in US

The Board of Unichem Laboratories will meet on 30 September 2024 to consider and approve integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned subsidiary of Company's holding company, Ipca Laboratories) into Unichem Pharmaceuticals (USA) Inc. (company's wholly owned subsidiary) so as to consolidate all the Ipca Group's USA generics formulations business under one entity.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Unichem Labs gains on proposal to consolidate USA generics formulations business under one entity

In an exchange filing made before market hours today, the company said that its board will consider integration and consolidation of the generics formulations business in the US market of Bayshore Pharmaceuticals LLC into Unichem Pharmaceuticals (USA) Inc. so as to consolidate all the Ipca Group's USA generics formulations business under one entity. Bayshore Pharmaceuticals LLC is a wholly owned subsidiary of Unichem's holding company Ipca Laboratories. Unichem Pharmaceuticals (USA) Inc. is the wholly owned subsidiary of Unichem Labs. Unichem Laboratories is a pharmaceutical company. It addresses the needs of therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management. The company had reported a consolidated net profit of Rs 9.26 crore in the quarter ended June 2024 as against net loss of Rs 0.67 crore during the previous quarter ended June 2023. Sales rose 5.49% to Rs 446.43 crore in Q1 FY25 over Q1 FY24. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Board of Unichem Laboratories appoints CFO

The Board of Unichem Laboratories at its meeting held on 08 August 2024 has approved appointment of Sanjay Jain as the Chief Financial Officer and Key Managerial Personnel of the Company with effect from 8 August 2024. Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Unichem Laboratories reports consolidated net profit of Rs 9.26 crore in the June 2024 quarter

Net profit of Unichem Laboratories reported to Rs 9.26 crore in the quarter ended June 2024 as against net loss of Rs 0.67 crore during the previous quarter ended June 2023. Sales rose 5.49% to Rs 446.43 crore in the quarter ended June 2024 as against Rs 423.19 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales446.43423.19 5 OPM %9.746.62 - PBDT43.3330.89 40 PBT15.002.12 608 NP9.26-0.67 LP Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Unichem Laboratories to table results

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

EU Court upholds Rs 126 cr fine imposed on Ipca Labs’ unit; stock jumps 4%

3 months agoBusiness Standard

Stocks to watch today: July 28, 2023

1 year agoThe Hindu Businessline

CCI approves Ipca Laboratories 59.38% stake buy deal in Unichem Laboratories

1 year agoThe Hindu Businessline

Better than most deals in recent years: Ipca on ‘expensive’ Unichem-buy

1 year agoThe Hindu Businessline